Search PubMed⌕ Search

Biomedical subjects

M Zeniya

Publications and source records attributed to M Zeniya.

51 records · Page 3Linked to original sources
PubMed1991

Ultrastructure of IL2-stimulated tumor-infiltrating lymphocytes showing cytolytic activity against tumor cells.

Tumor-infiltrating lymphocytes (TIL) obtained from tumor tissue and pleural effusion of breast carcinoma were cultured with interleukin-2 (IL2) and thus activated. The ultrastructure of TIL stimulated by IL2 to kill various breast carcinoma cells was then investigated. Freshly isolated TIL cultured with autologous tumor cells for 48 h without IL2 were small, round and showed neither binding to nor killing of tumor cells. TIL stimulated to proliferate by IL2 became effector cells and showed cytotoxicity against tumor cells. Ultrastructurally, the effector TIL resembled large granular lymphocytes, and adhered to tumor cells through interdigitation or close apposition of the two plasma membranes accompanied by spot-like close membrane contacts. At the site of each spot-like contact, there was a 5-nm intercellular space. The morphology of the TIL processes did not differ from those of LAK and other CTL or NK cell processes during contact, invagination or the killing of target cells. The granules in TIL were considered to participate in the cytotoxic effect. Phenotypically heterogeneous TIL, CD8+/CD57- and CD8+/CD57+, adhered to autologous tumor cells and MCF7 (human breast carcinoma cell line). However, it was unclear which cell or cells acted as the effector for tumor-cell killing.

Adult↗
PubMed1989

[The effect of local administration of recombinant interleukin-2 (rIL-2) on metastatic gastric tumor: report of an autopsy case].

The case is reported in which local administration of recombinant interleukin-2 (rIL-2) was successfully performed. A 54 year-old female who was operated on for advanced gastric cancer 15 years ago suffered from dyspnea and swelling of left anterior cervical lymph nodes. The histological examination of the cervical lymph node biopsied and cytological finding of pleural effusion confirmed the metastasis of adenocarcinoma. 11 x 10(6) unit of rIL-2 (S6820, Shionogi) per day was administered into the pleural cavity 8 times per month and this therapy was successful in decreasing a amount of pleural effusion. Simultaneously the number of tumor cells in pleural effusion was diminished, the CEA level in pleural effusion were also decreased and the LAK activities of prepared lymphocyte from pleural effusion were augmented. 6.5 x 10(6) unit of rIL-2 was also administered per day locally into the left anterior cervical lymph nodes 13 times per month and induced the decrease of lymph node swelling. A slight fever which can be controlled with antipyretic agent easily was only symptom after local administration of rIL-2. Besides the success of these treatment, the general condition gradually deteriorated. She died 6 month after admission. The autopsy revealed that only one anterior cervical lymph node was slightly enlarged and there is a few tumor cells in the lymphatic sinus. No other lymph node was found around the cervical area. There are a prominent pleural fibrous adhesion including only a few tumor cells infiltrated. These findings strongly indicated the clinical usefulness of local administration of rIL-2.

Adenocarcinoma↗
PubMed1988

The effect of bilirubin on biliary lipid secretion: analysis by horseradish peroxidase associated intrahepatic vesicular transport system.

The mechanism of biliary lipid secretion is still controversial and there is no definite information regarding how bilirubin inhibits biliary phospholipid and cholesterol secretions without affecting bile salt secretion. In this study, the effects of bilirubin on intrahepatic vesicular transport and biliary lipid secretion were examined using bile-fistula rats. Horseradish peroxidase (HRP) was used as a tracer of intrahepatic vesicular transport. Bilirubin (5 mg/100 g BW) and/or HRP (5 mg/100 gBW) were injected through the mesenteric vein. Bile flow, biliary bile acid, biliary phospholipid and cholesterol outputs were examined in saline, HRP and HRP + bilirubin groups, respectively. Bile flow and biliary bile acid output were not affected by bilirubin administration. Biliary phospholipid and cholesterol as well as biliary HRP outputs were inhibited just after bilirubin administration, 42.8 +/- 6.1 SD% 47.7 +/- 5.1 SD%, and 33.4 +/- 3.8 SD%, respectively. These results suggested the participation of intrahepatic vesicular transport system in the inhibition of biliary lipid secretion by bilirubin and in its secretory mechanism.

Animals↗
PubMed1988

Triton WR-1339-induced changes in serum lipids and biliary lipid secretion.

Biliary lipid secretion rates were measured in fed rats after an intravenous injection of Triton WR-1339 (TWR, 60 mg/100 g body wt), an agent that inhibits lipoprotein removal from the circulation. Serum triglyceride, phospholipid (PL), and cholesterol (CH) concentrations rose within 3 h of TWR to 45, 6.6, and 10 times control values, respectively, at 24-36 h. Serum lipids fell rapidly at 48 h and were normal by 72-96 h after TWR. TWR did not alter bile flow, hepatic bile acid transport, or biliary bile acid output. Within 0.5 h of TWR, biliary PL and CH outputs fell greater than 70%, and taurocholate-stimulated biliary PL secretion was markedly reduced. Biliary PL and CH secretion rates were approximately 30 and approximately 40% suppressed, respectively, 24 h after TWR, 160 and 330% elevated, respectively, at 48 h, and normally by 72 h, despite normal taurocholate-stimulated biliary PL secretion. Biliary beta-glucuronidase secretion (a lysosomal enzyme) was unchanged for 3 h after TWR but was increased at 24, 48, and 72 h, independent of biliary lipid secretion. Thus TWR acutely dissociates bile acid from lipid secretion without impairing bile acid transport or biliary lysosomal discharge. Late changes in biliary lipid secretion relate closely to TWR-induced change in serum lipid metabolism but not to stimulation of biliary lysosomal discharge.

Animals↗
PubMedDate not supplied

The effects of recombinant interleukin 2 on HBe antigen positive chronic hepatitis B.

Recombinant interleukin (IL-2) was administered to 16 patients with HBe antigen-positive chronic active hepatitis in which the diagnosis was ascertained histologically. In 7 of the 16 patients, a decrement of the serum HBe antigen value was observed (Group A). In group A, the findings showed an increment of peripheral Leu 11-positive cells and NK and LAK cell activity, an acute exacerbation during and after IL-2 administration, disappearance of HBc antigen observed in liver biopsy histology, and decrement of serum DNA-p activity. However, seroconversion of HBs antigen was not observed and no case showed the elimination status of continuous HB virus infection. On the other hand, in the other 9 patients (Group B), these changes were not observed and the existence of a HLA type difference between Group A and B was shown by HLA analysis. These results indicated that the immune responses mediated by IL-2 may play an important role in the development of chronic hepatitis B, and these results may be regulated genetically.

Adult↗